Nasdaq:US$18.12 (-0.52) | HKEX:HK$28.75 (-0.90) | AIM:£2.93 (-0.03)
Search Result
Previous Article   |   Next Article
Oncology / Immunology | 20 Nov 2018

Chi-Med Receives BayHelix R&D Achievement of the Year Award at BioCentury China Healthcare Summit

Shanghai: November 20, 2018: Hutchison China MediTech (“Chi-Med”) received “R&D Achievement of the Year” Award from BayHelix at the BioCentury China Healthcare Summit on November 14, 2018. Hutchison MediPharma, the Innovation Platform of Chi-Med, was recognized for the approval of fruquintinib for treating metastatic colorectal cancer in China. Fruquintinib is the first home-grown, China-discovered and developed drug in an oncology indication to be unconditionally approved through a randomized clinical trial in China.

The annual BayHelix China Healthcare Awards series celebrate outstanding individuals and companies for their achievements and contributions to the local healthcare ecosystem. The series include R&D Achievement of the Year, Deal of the Year, Commercial Achievement of the Year, Company of the Year and Person of the Year. In 2012, Chi-Med received “Alliance of the Year” Award for its collaboration with AstraZeneca on savolitinib, a potential global first-in-class inhibitor of the mesenchymal epithelial transition factor (c-MET) receptor tyrosine kinase.


Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 400 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med’s Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.

Dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market, Chi-Med is headquartered in Hong Kong and majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit:

Media Enquiries

UK & Europe – Anthony Carlisle, Citigate Dewe Rogerson

+44 7973 611 888 (Mobile)

Americas – Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile)

Hong Kong & Asia ex-China – Joseph Chi Lo, Brunswick

+852 9850 5033 (Mobile)

Hong Kong & Asia ex-China – Zhou Yi, Brunswick

+852 9783 6894 (Mobile)

Mainland China – Sam Shen, Edelman

+86 1367 179 1029 (Mobile)